Group 1 - The core viewpoint of the article highlights the development prospects and investment opportunities in the brain-computer interface (BCI) industry, particularly focusing on the segmentation of the market into invasive and non-invasive categories [1][9]. - The invasive BCI market is still in its early stages compared to the non-invasive market, primarily due to higher technical requirements and fewer companies involved in development [7][9]. - The article identifies key companies in the invasive BCI sector, such as JieTi Medical, which is set to complete its first human clinical trial by March 2025, and Brain Tiger Technology, which has achieved significant milestones in motion decoding experiments [8][9]. Group 2 - Invasive BCIs offer advantages such as precise measurement of neuronal impulses, high signal-to-noise ratio, and high resolution, but they also come with disadvantages like the risk of immune response and surgical trauma [5]. - The capital focus on invasive BCI has increased significantly, with financing share rising from 7% (2015-2019) to 44% (2020-2023), although it is expected to decrease to 27% in 2024-2025 [9]. - Non-invasive BCIs are the most common consumer-grade devices in the market, with numerous companies like QiangNerve Technology and RouLing Technology leading in this segment [11][12].

展望后市，麦肯锡预测，2030年全球脑机接口医疗应用市场规模达400亿美元（约合2900亿元人民 币），2040年扩大至约1450亿美元。中国已将脑机接口列为十大创新标志性产品之一，并有望凭借柔性 电极技术突破实现弯道超车。业内预计中国脑机接口市场2040年或突破1200亿元。 就在中国脑机接口相关研发、实践不断获得创新突破之际，美国Neuralink公司也完成多项突破。例如首 例人体脑机接口植入，患者可意念操控电脑光标，将大脑信号转化为数字指令，延迟也达到毫秒级。 2026年，Neuralink宣布获FDA设备认定，计划2026年启动百人临床试验；Neuralink还与美敦力合作开 发"神经修复系统"，获欧盟CE认证。 数据显示，截止2025年底，全球脑机接口企业突破800家，中国企业占比超25%，医疗健康领域应用占 比达56%，投融资规模逼近100亿美元，一场关乎"人机协同"的技术革命已进入攻坚突破的关键阶段。 据智通财经消息，日前，西北工业大学常洪龙、吉博文科研团队宣布，我国首次完成脑机接口太空在轨 验证。 据悉，该团队研发的脑机接口产品，在极端太空环境下持续稳定采集模拟体液环境中的脑电信号，噪声 水平 ...